Progress in Diagnostic Technology Expected to Improve HIV/AIDS Detection
Diagnostic technology has evolved at a rapid pace over the past decade, owing to significant breakthroughs in research and development. Within the HIV/AIDS immunoassay diagnostics market landscape, the demand for automated clinical laboratory has paved the way for efficient and reliable antibodies and antigen identification techniques. Despite significant progress, the human immunodeficiency virus (HIV) continues to be a major global health problem and a medical challenge. Some of the most effective and critical HIV management strategies include antiretroviral therapy (ART) initiation, early diagnosis, and assessment of the viral load.
HIV diagnostic tests offer two solutions - detection of virus molecules (p24 antigen and HIV RNA) and/or different antibodies to the virus. HIV/AIDS immunoassays, in particular, are used to detect antibodies and p24 antigen. Due to the growing need to curb HIV/AIDS and other types of HIV infections, the demand for efficient diagnostic techniques has increased significantly worldwide. The global HIV/AIDS immunoassay diagnostics market is expected to expand from ~US$ 570 Mn in 2019 to a value of ~US$ 870 Mn by 2027.
To know the scope of our report Get a Sample on HIV/AIDS Immunoassay Diagnostics Market
Growing Focus on Improving Effectiveness of HIV Diagnostics – A Rising Trend
Around 38 million individuals across the world had HIV in 2018 of which, approximately 36 million were adults. Furthermore, ~1.7 million new HIV cases were registered in 2018 and the numbers continue to grow, especially in the sub-Saharan region and low-income economies. Key participants involved in the HIV/AIDS immunoassay diagnostics market are focusing on simplifying and improving the effectiveness of HIV diagnostics.
Antibody screening tests including the enzyme linked immunosorbent assay (ELISA) are predominantly used to measure antibodies in blood. This test is generally the first test ordered by healthcare professionals to detect HIV antigens in the blood. Traditionally, enzyme-linked immunosorbent assays are complex, expensive, and often require a skilled professional. However, as ELISA is easier and safer than radioimmunoassay (RIA); its adoption will continue to grow at a steady pace over the forecast period (2019-2027). Thus, the ELISA segment is projected to create an incremental opportunity of ~US$ 112 Mn between the stipulated timeframe of the study. The diagnostic results using ELISA could take a few days, which has led to the need for rapid testing techniques.
Get a glimpse of the in-depth analysis through our Report Brochure
Despite steady growth of the ELISA segment, the chemiluminescent immunoassay segment (CLIA) segment is expected to hold a larger share of the HIV/AIDS immunoassay diagnostics market, in terms of value. By the end of 2027, the CLIA segment is likely to account for ~48% of the total share of the HIV/AIDS immunoassay diagnostics market and witness a CAGR of ~6% during the forecast period. Over the past few years, CLIA has gained significant popularity in various sectors, including clinical diagnosis, life sciences, pharmaceutical analysis, and environmental monitoring, among others due to factors such as optimum specificity, easy-to-use equipment, wider linear range, and high sensitivity. Techniques based on chemiluminescent are increasingly being used for clinical analysis and several biomedical research activities.
Market Players to Focus on Efficiency and Expanding Product Portfolio
Presently, major players operating in the global HIV/AIDS immunoassay diagnostics market are striving to offer effective, reliable, cost-effective HIV/AIDS immunoassay diagnostics. In addition, increasing prevalence of HIV/AIDS and HIV infections worldwide have prompted market participants to provide new and improved HIV testing technologies. Companies are focusing on improving patient outcomes and minimizing disease transmission, which requires reliable and accurate clinical laboratory testing. For instance, Siemens Healthineers launched the Atellica ® IM and ADVIA Centaur ® HIV Combo to improve the detection of HIV infections. The entry of new technologies, including the third-generation enzyme immunoassay, which detects IgM and IgG antibodies and fourth-generation enzyme immunoassay that detect HIV p24 and HIV antibodies, are some of the most recent groundbreaking developments in the global HIV/AIDS immunoassay market.
Moreover, product development is likely to fuel the global HIV/AIDS immunoassay market, as companies are seeking approvals from the U.S. FDA. For instance, Shenzen New Industries Biomedical Engineering Co., Ltd (SNIBE) became the first China-based company in the HIV/AIDS immunoassay diagnostics market to receive the approval from the U.S. FDA for the newly developed automated immunoassay analyzer.
Expanding operations in future? To get the perfect launch ask for a custom report
More Trending Reports by Transparency Market Research – https://www.biospace.com/article/respiratory-antiviral-treatment-market-trends-analysis-influenza-segment-to-experience-strong-growth/
Comments
Post a Comment